GlassScriptPhysician profile
William D Naber
NPI 1912093626
$9,142.69
in general payments reported to CMS, 2019-2025
31 companies · $1,301 in 2025
The $1,301 reported for 2025 was more than what 94% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,822 · 2020: $964 · 2021: $1,498 · 2022: $791 · 2023: $749 · 2024: $2,017 · 2025: $1,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,067.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,673.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,055.97 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $798.92 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $626.16 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $610.64 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $563.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $388.69 | 2024-2025 | |
| Amgen INC. | $367.22 | 2020-2025 | Otezla, Repatha, Repatha |
| Optinose US, INC. | $348.96 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $302.70 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $292.35 | 2019-2021 | |
| Glaxosmithkline, LLC. | $251.78 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Redhill Biopharma INC. | $242.99 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $218.96 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $210.24 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $164.59 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $128.14 | 2019-2023 | Verquvo, Belsomra, Januvia |
| Phathom Pharmaceuticals, INC. | $126.03 | 2024 | Voquezna |
| Eisai INC. | $114.60 | 2021 | |
| Bausch Health US, LLC | $111.00 | 2022-2023 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $91.34 | 2023-2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $87.30 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.45 | 2022 | |
| Janssen Pharmaceuticals, INC | $56.24 | 2019-2020 | |
| Exact Sciences Corporation | $56.11 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $51.63 | 2022-2023 | Myrbetriq |
| Currax Pharmaceuticals LLC | $34.28 | 2023 | Contrave, Nexletol, Nexlizet |
| Sumitomo Pharma America, INC. | $32.61 | 2023 | Gemtesa |
| Regeneron Healthcare Solutions, INC. | $31.55 | 2019 | |
| Shield Therapeutics INC | $28.94 | 2025 | |
| Arbor Pharmaceuticals, INC. | $19.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Naber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.